BMS acquires DuPont Pharma
New York-based Bristol-Myers Squibb Co. announced that its $7.8 billion acquisition of Wilmington, DE-based DuPont Pharmaceuticals Co. from DuPont is complete. The acquisition, which was announced on June 7, closed on October 1.
New York-based Bristol-Myers Squibb Co. announced that its $7.8 billion acquisition of Wilmington, DE-based DuPont Pharmaceuticals Co. from DuPont is complete. The acquisition, which was announced on June 7, closed on October 1.
"The acquisition of DuPont Pharma will make Bristol-Myers Squibb an even stronger pharmaceutical company," said Peter R. Dolan, chairman and chief executive officer of Bristol-Myers Squibb. "It will enable us to play a greater leadership role, particularly in the areas of virology and cardiovascular diseases, where there is a pressing need to expand treatments and find new and better therapies. Our combined research and development pipelines and truly innovative discovery efforts will usher in medical advances for years to come in many areas of great human need."
New products
With this acquisition, Bristol-Myers Squibb gains several products, including Sustiva⢠(efavirenz), a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV/AIDS; Coumadin® (warfarin sodium tablets, USP), an oral blood anticoagulant; and Cardiolite® (kit for the preparation of Technetium Tc99m Sestamibi for injection), a cardiovascular medical imaging agent. Bristol-Myers Squibb also gains an R&D pipeline that includes compounds in five therapeutic areas - virology, cardiovascular diseases, inflammatory diseases, cancer and disorders of the central nervous system.
Under the terms of the agreement, Bristol-Myers Squibb paid $7.8 billion in cash for DuPont Pharma. As a result of the transaction, the company expects to record a one-time, in-process R&D write-off and restructuring liability in the range of $2 billion to $3 billion. PR
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
